GWN323 + PDR001

GWN323 + PDR001 is an investigational combination therapy consisting of two monoclonal antibodies: **GWN323**, which targets and agonizes the glucocorticoid-induced tumor necrosis factor receptor (GITR) on T-cells, and **PDR001** (also known as spartalizumab), which blocks the PD-1 receptor, a key immune checkpoint. GWN323's mechanism stimulates T-effector cells and dampens T-regulatory cell activity, enhancing anti-tumor immune function, while PDR001 blocks PD-1 mediated immunosuppression, further promoting the immune system's activity against cancer cells. This combination is developed by Novartis for the treatment of advanced or metastatic solid tumors and lymphomas, aiming to improve anti-tumor responses by dual modulation of immune pathways[1][2][3][5][7].

Other names

GWN323 + spartalizumab